Aspirine et maladie de Horton

Weyand, 2003, Giant-cell arteritis and polymyalgia rheumatica, Ann Intern Med, 139, 505, 10.7326/0003-4819-139-6-200309160-00015 Nordborg, 1989, Death rate and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy, Br Med J, 299, 549, 10.1136/bmj.299.6698.549 Uddhammar, 2002, Increased mortality due to cardiovascular disease in patients with giant cell arteritis in Northern Sweden, J Rheumatol, 29, 737 Matteson, 1996, Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort, Am J Med, 100, 193, 10.1016/S0002-9343(97)89458-2 Save-Soderbergh, 1986, Giant cell arteritis as a cause of death, JAMA, 255, 493, 10.1001/jama.1986.03370040067025 Cullen, 1976, Ophtalmic complications of giant cell arteritis, Surv Ophtalmol, 20, 247, 10.1016/0039-6257(76)90224-1 Hayreh, 1991, Ophtalmic features of giant cell arteritis, Clin Rheumatol, 3, 431 Caselli, 1988, Neurologic disease in biopsy proven giant cell (temporal) arteritis, Neurology, 38, 352, 10.1212/WNL.38.3.352 Aiello, 1993, Visual prognosis in giant cell arteritis, Ophtalmology, 4, 550, 10.1016/S0161-6420(93)31608-8 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ, 324, 71, 10.1136/bmj.324.7329.71 Lévesque, 2002, L’aspirine en prévention primaire de la maladie athéromateuse: des indices mais encore des incertitudes, J Mal Vasc, 27, 263 Weyand, 2002, Therapeutic effects of acetylsalicylic acid in giant cell arteritis, Arthritis Rheum, 46, 457, 10.1002/art.10071 Brack, 1997, Giant cell vasculitis is a T cell-dependent disease, Mol Med, 3, 530, 10.1007/BF03401699 Brack, 1999, Disease pattern in cranial and large-vessel giant cell arteritis, Arthritis Rheum, 42, 311, 10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F Weyand, 1997, Disease patterns and tissue cytokine profiles in giant cell arteritis, Arthritis Rheum, 40, 19, 10.1002/art.1780400105 Kaiser, 1998, Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis, Arthritis Rheum, 41, 623, 10.1002/1529-0131(199804)41:4<623::AID-ART9>3.0.CO;2-6 Duhaut, 2003, Facteurs prédictifs de cécité et de troubles visuels dans la maladie de Horton, Rev Med Interne, 24, 50, 10.1016/S0248-8663(03)80058-9 Liozon, 2001, Facteurs prédictifs de complications céphaliques ischémiques irréversibles au cours de la maladie de Horton : étude prospective sur 178 patients, Rev Med Interne, 22, 30, 10.1016/S0248-8663(00)00283-6 Liozon, 2001, Risk factors of visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients, Am J Med, 111, 211, 10.1016/S0002-9343(01)00770-7 Gonzalez-Gay, 1998, Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment, Arthritis Rheum, 41, 1497, 10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z Nesher, 2004, Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis, Arthritis Rheum, 50, 1332, 10.1002/art.20171 Lévesque, 2004, Les effets non lipidiques des statines au cours de l’athérosclérose, Rev Med Interne, 25, 783, 10.1016/S0248-8663(04)00264-4 Loke, 2003, Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient, Br J Clin Pharmacol, 55, 282, 10.1046/j.1365-2125.2003.01774.x